

Quarterly Research and Innovation Report

Author: Nigel Brunskill Sponsor: Andrew Furlong

Trust Board paper H

Purpose of report:

This paper is for:	Description	Select (X)
Decision	To formally receive a report and approve its recommendations OR a particular course of action	
Discussion	To discuss, in depth, a report noting its implications without formally approving a recommendation or action	
Assurance	To assure the Board that systems and processes are in place, or to advise a gap along with treatment plan	X
Noting	For noting without the need for discussion	

Previous consideration:

Meeting	Date	Please clarify the purpose of the paper to that meeting using the categories above
CMG Board (specify which CMG)		
Executive Board		
Trust Board Committee		
Trust Board		

Executive Summary

Context

The report summarises R&I activities over the last quarter. It notes aspects of performance, projects in place and under development. Possible changes to R&I workforce are discussed.

Questions

1. Is R&I performance and delivery acceptable?
2. Are significant achievements highlighted in the paper?
3. Are major projects highlighted in the paper?

Conclusion

1. R&I performance is currently acceptable.
2. A number of significant achievements are evident.
3. A number of relevant new projects are in development.

Input Sought

We would welcome the Trust Board’s input regarding discussion and approval of current activities.

For Reference:

This report relates to the following UHL quality and supporting priorities:

1. Quality priorities

Safe, surgery and procedures	[Yes]
Safely and timely discharge	[Yes]
Improved Cancer pathways	[Yes]
Streamlined emergency care	[Yes]
Better care pathways	[Yes]
Ward accreditation	[No]

2. Supporting priorities:

People strategy implementation	[No]
Estate investment and reconfiguration	[No]
e-Hospital	[Yes]
More embedded research	[Yes]
Better corporate services	[Yes]
Quality strategy development	[Yes]

3. Equality Impact Assessment and Patient and Public Involvement considerations:

- What was the outcome of your Equality Impact Assessment (EIA)?
N/A
- Briefly describe the Patient and Public Involvement (PPI) activities undertaken in relation to this report, or confirm that none were required
PPI is central to research activity and is embedded at all levels
- How did the outcome of the EIA influence your Patient and Public Involvement ?
- If an EIA was not carried out, what was the rationale for this decision?

4. Risk and Assurance

Risk Reference:

Does this paper reference a risk event?	Select (X)	Risk Description:
Strategic: Does this link to a <i>Principal Risk</i> on the BAF?	X	Principal Risk 11: Development of LAHP
Organisational: Does this link to an <i>Operational/Corporate Risk</i> on Datix Register		
New Risk identified in paper: What <i>type</i> and <i>description</i> ?		
None		

- 5. Scheduled date for the **next paper** on this topic: TBC
- 6. Executive Summaries should not exceed **5 sides** [My paper does comply]

UHL R&I Quarterly Trust Board Report January 2020

1. Introduction


This report describes current R&I performance against metrics, projects under development, new challenges and potential threats.

2. Research Performance

The activity of UHL in initiating and delivering clinical research is performance monitored by both the NIHR Central Commissioning Facility (NIHR CCF) and the East Midlands Clinical Research Network (EM CRN). In turn the UHL R&I Office reports research CMG level activity and performance to each CMG via the R&I Executive Committee.

2.1 NIHR CCF

UHL is judged by its performance in initiating new trials and then delivering clinical trials to time and target. In Q2 2019/20 this figure was excellent and represents a sustained performance. In terms of initiating research, UHL is in 11th place (out of 201 Trusts) in League 1 (of 6) having submitted 113 trials for analysis (max 186, min 1). Time between date site selected and first patient recruited by trust – League 1 is shown below.




Time between site selected and first patient recruited by trust – League 1.

In regards to delivering research UHL is also in League 1, in 14th position having reported 32 trials for analysis.

2.2. EM CRN

Cumulative recruitment into non-portfolio and NIHR CRN portfolio clinical trials so far for 19/20 is shown below.



3.0 Recent Applications and Awards

3.1 NIHR Leicestershire Academic Health Science Centre (LeAHSC).

Building on Leicestershire Academic Health Partners, an application for LeAHSC designation was made in December 2019. This brings together UHL, University of

Leicester, Leicestershire Partnership NHS Trust and the East Midlands Academic Health Science Network. The outcome will be known in February 2020.

3.2 NIHR Leicestershire Patient Recruitment Centre (LePRC).

NIHR announced the establishment of five PRCs across England to increase participation in late-phase commercial research studies. UHL has bid to host a LePRC at the Leicester General Hospital based in the Leicester Diabetes Centre. If successful, this will provide a resource across the Leicestershire integrated Care system in partnership with primary care and LPT. The outcome will be known in January 2020.

3.3 The COLO-PREVENT Study

A University of Leicester team lead by Prof Anne Thomas have been awarded c£6M by Cancer Research UK to fund a large prevention of colonic carcinoma trial.

4.0 Recent and Upcoming Events

4.1 House of Commons Science and Technology Select Committee

The UHL Director of R&I gave evidence to the HoC STC in October 2019 on the subject of research transparency because UHL had greatly improved public reporting of clinical trial results.

4.2 NIHR Strategy Board Leicester Meeting

The NIHR Strategy Board met at the University of Leicester College Court on 14th November. In the afternoon a 'Question Time' event was held with attendees from across the East Midlands.

4.3 The 2020 UK CRF Network Conference

Planning is well underway for this event which will be held in Leicester entitled: '**Research for All: Enabling Equal Access to Clinical Research**'. This will be a two-day event held at the University of Leicester City Campus with the support of the University of Leicester Conference Team. A gala dinner is planned for the evening of the first day to be held at **Athena**, in the cultural quarter of the city. Around 400 conference delegates are expected to attend.

4.4 Leicester's Research Live – '**Becoming the Best in Research**'

This biannual event will be held at Leicester Tigers Stadium on 25th February 2020. The programme for the day includes talks, workshops (for example, using quality improvement tools, an introduction to working with commercial companies, and gaining insights from our public research engagement panel), plus opportunities to network and share ideas with other research teams.

4.5 UHL Research and Innovation Team External Peer Review

The R&I Team at UHL will be the first to be subject to voluntary external peer review. This process developed by the UKRD, R&D Leaders in the NHS group, will be piloted at the Trust in February 2020. The peer review will be performed by a visiting R&I team from Leeds Teaching Hospitals in Feb 2020. The UHL R&I Team will reciprocate the process by visiting Leeds to peer review the R&I functions there.

4.6 UHL Quarterly R&I Forum

In the 2019 R&I staff survey, research staff said they wanted more opportunities for direct contact with the research and innovation service and to feel valued and included in decision making processes. One of the ways we have addressed this is

by introducing Quarterly R&I Forums rotating between sites. The next is at LRI in January 2020.

5.0 UHL Research Workforce Listening in Action

Two Listening in Action Events were held in June/July 2019. All research staff from across the Trust were invited, and over 150 attended to contribute and share ideas about the optimum structure of a modern research delivery workforce. The results have been analysed and a report with recommended actions has been approved by the Executive Strategy Board in October 2019.

As a first step to establish a 'One UHL Research Team' research staff will move from CMGs to the R&I Dept. An Associate Director of R&I has been appointed to assist with implementation of other actions.